Actively Recruiting
The SAFE Prospective Registry
Led by University Hospital Ostrava · Updated on 2023-09-07
60
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.
CONDITIONS
Official Title
The SAFE Prospective Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Atrial fibrillation (paroxysmal or persistent)
- Patients indicated for catheter ablation and/or electrical cardioversion
- Signed informed consent
You will not qualify if you...
- Longstanding or permanent atrial fibrillation
- Severe mitral regurgitation
- Heart failure with permanently reduced ejection fraction
- Cerebral ischaemic stroke in less than 3 months
- Severe kidney injury
- Severe renal insufficiency
- Hepatic insufficiency limiting biomarker sampling
- Myocardial infarction less than 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Ostrava
Ostrava, Moravian-Silesian Region, Czechia, 70852
Actively Recruiting
Research Team
J
Jiří Hynčica
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here